Comorbidities and Events of Clinical Interest in Patients with Pulmonary Arterial Hypertension (PAH): Analysis of Real‐World Data
= 16,749), hypertension, heart failure, diabetes, and CKD were common. Incidence rates (per 100 person-years) for thrombocytopenia and major bleeding were 8.2 and 7.3, respectively.
Authors
- Ioana R. Preston (ORCID: https://orcid.org/0000-0002-1378-7362)
- Tammy Jiang (ORCID: https://orcid.org/0000-0002-6887-5706)
- Jackie Lucia
- Michelle Skornicki (ORCID: https://orcid.org/0000-0002-2594-2569)
- Alexandra G. Cornell
- Dena Rosen Ramey (ORCID: https://orcid.org/0000-0002-2238-2930)
- Dionna Andrean
- Harald Sinclair Mackenzie
Institutions
- Tufts University (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Aetion (United States) (US)
Publication Details
- Journal
- Pulmonary Circulation
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1002/pul2.70288
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck